TiGenix raises $35.65 million gross proceeds with NASDAQ IPO
Leuven (BELGIUM) – December 15, 2016, 3:00h CET – TiGenix NV (Euronext Brussels: TIG; “TiGenix”), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the pricing of its initial public offering in the United States (the “Offering”) totalling $35.65 million gross proceeds from the sale of 2,300,000 American Depository Shares (“ADSs”), representing 46,000,000 ordinary shares, at a price to the public of $15.50 per ADS.
In connection with the Offering, TiGenix has granted the underwriters a 30-day option to purchase up to an additional 345,000 ADSs, representing 6,900,000 ordinary shares, to cover over-allotments, if any.
The closing of the Offering is expected to occur on December 20, 2016, subject to the satisfaction of customary closing conditions.
Each of the ADSs offered represents the right to receive twenty (20) ordinary shares.
TiGenix’s ordinary shares are currently listed on Euronext Brussels. The ADSs are expected to begin trading on NASDAQ on December 15, 2016 under the symbol “TIG”.
BofA Merrill Lynch and Cowen and Company, LLC are acting as joint book-running managers, Canaccord Genuity is acting as lead manager and BTIG is acting as co-manager for the Offering.
The Offering of ADSs will be made only by means of a prospectus. A copy of the final prospectus, when available, can be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: firstname.lastname@example.org and from Cowen and Company LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.
A registration statement relating to these securities was filed with and declared effective by the U.S. Securities and Exchange Commission on December 14, 2016. The registration statement can be accessed through the SEC’s website at www.sec.gov.
This press release is for information purposes only and does not constitute, and should not be construed as, an offer to sell or the solicitation of an offer to buy or subscribe to any securities of TiGenix, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. This press release is not for publication or distribution, directly or indirectly, in or into any state or jurisdiction into which doing so would be unlawful.